title: Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
abstract: BACKGROUND
  The role of cellular drug resistance in childhood acute myeloid leukemia (AML) has not yet been established. The aim of the study was the analysis of the clinical value of ex vivo drug resistance in pediatric AML.
  
  
  METHODS
  A cohort of 90 children with de novo AML were assayed for drug resistance profile by the 3-4,5-dimethylthiazol-2-yl-2,5-difenyl tetrazolium bromide (MTT) assay and prognostic model of in vitro drug sensitivity was analyzed.
  
  
  RESULTS
  Children who relapsed during follow-up showed higher in vitro resistance of leukemic blasts to most of the drugs tested, except for cytarabine, cladribine, vincristine, mercaptopurine and thioguanine. A combined in vitro drug resistance profile to fludarabine, treosulfan and mitoxantrone (FTM score) was defined and it had an independent prognostic significance for disease free survival in pediatric AML.
  
  
  CONCLUSIONS
  The combined fludarabine, treosulfan and mitoxantrone resistance profile to possibly may be used for better stratification of children with AML or indicate the necessity for additional therapy.
authors.affiliation: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland. jstyczynski@cm.umk.pl
authors.forename: Jan
authors.initials: J
authors.lastname: Styczynski
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Dluzniewska
authors.forename: Edyta
authors.initials: E
authors.lastname: Juraszewska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Czyzewski
authors.forename: Maria
authors.initials: M
authors.lastname: Wieczorek
authors.forename: Igor
authors.initials: I
authors.lastname: Olejnik
authors.forename: Maryna
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: Marta
authors.initials: M
authors.lastname: Kuzmicz
authors.forename: Jerzy
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: Jolanta
authors.initials: J
authors.lastname: Stefaniak
authors.forename: Wanda
authors.initials: W
authors.lastname: Badowska
authors.forename: Danuta
authors.initials: D
authors.lastname: Sonta-Jakimczyk
authors.forename: Tomasz
authors.initials: T
authors.lastname: Szczepanski
authors.forename: Michal
authors.initials: M
authors.lastname: Matysiak
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Stanczak
authors.forename: Iwona
authors.initials: I
authors.lastname: Malinowska
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Benigna
authors.initials: B
authors.lastname: Konatkowska
authors.forename: Lidia
authors.initials: L
authors.lastname: Gil
authors.forename: Anna
authors.initials: A
authors.lastname: Balcerska
authors.forename: Lucyna
authors.initials: L
authors.lastname: Kapuscinska
authors.forename: Joanna
authors.initials: J
authors.lastname: Szczepanek
authors.forename: Beata
authors.initials: B
authors.lastname: Kolodziej
authors.forename: Beata
authors.initials: B
authors.lastname: Rafinska
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kubicka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D011379:Prognosis; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D008942:Mitoxantrone; C018404:treosulfan; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine